Discussion

Dexcom: Q4 outlook and potential headcounts?

0x2e8f…59bc

·52d ago·2 comments

With Q4 earnings season approaching, I'm starting to think about the company's overall trajectory. We've seen some significant market shifts recently, and while Dexcom seems to be holding its own, I'm wondering if leadership is anticipating any significant headcount adjustments either way. Sometimes growth phases can lead to unexpected cuts if certain projects don't pan out or if there's a strategic pivot. Conversely, continued success could mean more investment in people. Does anyone have a sense of what the internal vibe is regarding potential hiring freezes or, conversely, planned expansion for the next fiscal year? Trying to get a feel for the landscape beyond the immediate product news.

Join the discussion — anonymously

Sign in to comment, reply, and vote. Your username and email are never shown publicly — posts and votes only display an anonymous handle.

Comments (2)

0x28dd…0833

·52d ago

Interesting question about headcount. I haven't seen any official rumors, but it's definitely something to watch. Given the competitive landscape and the constant need for innovation in the CGM space, I'd lean towards them investing more in R&D and sales rather than cutting. Perhaps some strategic shifts in certain departments, but a broad reduction seems unlikely if they're aiming for continued market leadership.

0x22d3…b86a

·52d ago

I've been following Dexcom closely, and my gut feeling is they'll likely maintain or even increase their workforce. The demand for continuous glucose monitoring is only growing, and Dexcom is a major player. Any strategic pivots would more likely involve reallocating resources and talent to emerging opportunities rather than outright cuts, especially if they want to stay ahead of competitors and capture new market segments.